Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.47 |
| ▸ | F2 | P00734 | 5/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151232 | 0.98 | F10 (0.48) | F10F2ITGB3ITGA2B | |
| SCHEMBL5137792 | 0.87 | F10 (0.51) | F10F2ITGB3ITGA2B | |
| SCHEMBL3151179 | 0.86 | F10 (0.62) | F10F2ITGB3ITGA2B | |
| SCHEMBL3155707 | 0.86 | F10 (0.62) | F10F2ITGB3ITGA2B | |
| SCHEMBL3155824 | 0.86 | F10 (0.61) | F10F2ITGB3ITGA2B | |
| SCHEMBL3152468 | 0.84 | F10 (0.49) | F10F2ITGB3ITGA2B | |
| SCHEMBL3151177 | 0.84 | F10 (0.49) | F10F2ITGB3ITGA2B | |
| SCHEMBL3156206 | 0.84 | F10 (0.64) | F10F2ABCB11ST14 | |
| SCHEMBL3155698 | 0.84 | F10 (0.56) | F10F2ABCB11ST14 | |
| SCHEMBL3150504 | 0.84 | F10 (0.62) | F10F2ITGB3ITGA2BABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2099453-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1933841-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008052671-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |